Clinical trial
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell…
NCT00377052 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00377052 |
|---|---|
| Title | Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma |
| Official title | A Phase II Study of Bortezomib and Gemcitabine in Patients With Relapsed Mantle Cell Lymphoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib, gemcitabine hydrochloride |
| Enrollment | 29 |
| Start date | Jan 16, 2007 |
| Primary completion | Apr 21, 2009 |
| Completion | Jun 21, 2011 |
| First posted | Sep 15, 2006 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: